Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 10Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 5Recurrence 3Prostatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lung Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Head and Neck Neoplasms 2Glioblastoma 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Thymoma 1Skin Neoplasms 1Salivary Gland Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Non Castrate Metastatic Prostate Cancer 1Neoplasms 1Nasopharyngeal Neoplasms 1

Interventions

Cyclophosphamide 328Methotrexate 182Cytarabine 164fludarabine phosphate 151Vincristine 128Dexamethasone 126fludarabine 123Peripheral Blood Stem Cell Transplantation 116Whole-Body Irradiation 108Etoposide 106Mycophenolic Acid 105Tacrolimus 95Busulfan 95Filgrastim 93Melphalan 81Cyclosporine 80Rituximab 79Doxorubicin 79Mercaptopurine 69Radiotherapy 62Antilymphocyte Serum 62Granulocyte Colony-Stimulating Factor 57Prednisone 56blinatumomab 55pegaspargase 54Asparaginase 54Thiotepa 52Daunorubicin 52Calcium Dobesilate 47Clofarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Precursor Cell Lymphoblastic Leukemia-Lymphoma × NVP-BKM120 × Clear all
NCT01396499 2016-11-01

Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias

M.D. Anderson Cancer Center

Phase 1 Completed
16 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡